Magnetic resonance spectroscopy evidence for declining gliosis in MS patients treated with ocrelizumab versus interferon beta-1a.

Erin L MacMillanJulia J SchubertIrene M VavasourRoger TamAlexander RauscherCarolyn TaylorRick WhiteHideki GarrenDavid ClaytonVictoria LevesqueDavid Kb LiShannon H KolindAnthony L Traboulsee

Published in: Multiple sclerosis journal - experimental, translational and clinical (2019)

Results from this exploratory study suggest that over 2 years, ocrelizumab reduces gliosis compared with interferon beta-1a, demonstrated by declining ml, and stable tCr and tCho. Ocrelizumab may improve the physiologic milieu by decreasing neurotoxic factors that are generated by inflammatory processes.

Keyphrases

dendritic cells
mass spectrometry
multiple sclerosis
regulatory t cells
oxidative stress
ms ms